Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Hangzhou Huadong Medicine Group Kangrun Pharmaceutical","sponsor":"Immunogen","pharmaFlowCategory":"D","amount":"$305.0 million","upfrontCash":"$40.0 million","newsHeadline":"ImmunoGen and Huadong Medicine Announce Strategic Collaboration to Develop and Commercialize Mirvetuximab Soravtansine in Greater China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"Hangzhou Huadong Medicine Group Kangrun Pharmaceutical","sponsor":"Insilico Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Huadong Medicine and Insilico Medicine Enter Co-Development Partnership to Advance Oncology Drug Discovery by Hitting Undruggable Targets","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"CHINA","productType":"Small molecule","productStatus":"Undisclosed","date":"September 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery"}]

    Find Clinical Drug Pipeline Developments & Deals by Hangzhou Huadong Medicine Group Kangrun Pharmaceutical

    Menu

    Hangzhou Huadong Medicine Group Kangrun Pharmaceutical

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Hangzhou Huadong Medicine Group Kangrun Pharmaceutical

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Huadong Medicine and Insilico Medicine Enter Co-Development Partnership to Advance Oncology Drug Discovery by Hitting Undruggable Targets

              Details:

              The collaboration will leverage Huadong Medicine's advanced innovative drug discovery and screening characterization platform, in combination with Insilico's end-to-end AI-driven drug discovery platform.

              Lead Product(s): Undisclosed

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Small molecule

              Partner/Sponsor/Collaborator: Insilico Medicine

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration September 08, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Hangzhou Huadong Medicine Group Kangrun Pharmaceutical

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              ImmunoGen and Huadong Medicine Announce Strategic Collaboration to Develop and Commercialize Mirvetuximab Soravtansine in Greater China

              Details:

              Partnership accelerates development path for Mirvetuximab in Greater China and expands Huadong Medicine’s oncology portfolio with innovative ADC.

              Lead Product(s): Mirvetuximab Soravtansine

              Therapeutic Area: Oncology Product Name: IMGN853

              Highest Development Status: Phase III Product Type: Large molecule

              Recipient: Immunogen

              Deal Size: $305.0 million Upfront Cash: $40.0 million

              Deal Type: Collaboration October 19, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              Temad- We think of world-class quality.
              Post Enquiry
              POST ENQUIRY